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Abstract 22 
Intrauterine growth restriction (IUGR) is a serious pregnancy complication affecting 23 
approximately 8% of all pregnancies. The aetiology is believed to be insufficient maternal 24 
uteroplacental perfusion which prevents adequate nutrient and oxygen availability for the 25 
fetus. There is no treatment that can improve uteroplacental perfusion and thereby increase 26 
fetal growth in the uterus.  27 
Maternal uterine artery gene therapy presents a promising treatment strategy for IUGR, with 28 
the use of adenoviral vectors encoding for proteins such as Vascular Endothelial Growth 29 
Factor (VEGF) demonstrating improvements in fetal growth and neonatal outcome in 30 
preclinical studies. Mechanistically, maternal VEGF gene therapy delivered to the uterine 31 
arteries increases uterine blood flow and enhances vascular relaxation short term, while 32 
reducing vascular contractility long term. It also leads to vascular remodeling with increased 33 
endothelial cell proliferation in the perivascular adventitia of uterine arteries. Safety 34 
assessments suggest no vector spread to the fetus and no adverse risk to the mother or fetus; a 35 
clinical trial is in development. This article assesses research into VEGF maternal uterine 36 
artery directed gene therapy for IUGR, investigating the use of transgenes and vectors, their 37 
route of administration in obstetrics, and the steps that will be needed to take this treatment 38 
modality into the clinic. 39 
 40 
 41 
 42 
 43 
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Intrauterine growth restriction 45 
Optimal fetal growth depends on normal functioning maternal, placental and fetal factors and 46 
the external environmental, on the background of a genetically pre-determined growth 47 
potential. Intrauterine growth restriction (IUGR) can occur due to a malfunction of one or a 48 
number of these factors. IUGR is potentially life threatening and affects 8% of all 49 
pregnancies, contributing to 50% of stillbirths (1).  Of those diagnosed with IUGR, 50 
approximately 1 in 500 cases are classified as both severe and early onset, occurring before 51 
28 weeks of gestation. Severe IUGR can be caused by structural abnormalities of the fetus, 52 
maternal medical disorders and congenital infections, but most commonly, it is impaired 53 
uteroplacental function that restricts delivery of nutrients to the fetus, resulting in slowing or 54 
even cessation of fetal growth, termed placental insufficiency.  55 
In normal pregnancies, effective first-trimester infiltration of the trophoblast in the maternal 56 
spiral arteries leads to the creation of a high flow, low resistance maternal circulation. 57 
Angiogenesis and vasodilation in the placenta are enhanced by the production of factors such 58 
as placental growth factor (PIGF), vascular endothelial growth factor (VEGF) and insulin-59 
growth factor (IGF) (2,3), which facilitates a reduction in placental resistance. The obstetric 60 
syndromes of pre-eclampsia and IUGR appear to be interrelated through VEGF biology. An 61 
increase in soluble fms-like tyrosine kinase 1 (sFlt1), which acts as a soluble receptor for 62 
VEGF in the maternal circulation, is observed in both conditions (4). High sFlt1 is a key 63 
pathological hallmark of pre-eclampsia and IUGR (5,6)(7). Increasing available VEGF 64 
through its local overexpression may be a good therapeutic approach in these conditions. 65 
Treatments based on the manipulation of VEGF and related angiogenic factors are therefore 66 
likely to be effective for IUGR and pre-eclampsia (Figure 1)(8).  67 
When severe and early in onset, management of affected pregnancies involves prompt 68 
delivery of the fetus before death or irreversible organ damage occurs, particularly to the 69 
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brain. However, delivering the fetus in severe early onset IUGR adds additional risks to the 70 
baby from extreme prematurity (9). In this situation the question of viability also arises, and 71 
decision making with parents is challenging (10). Substantial improvements in morbidity and 72 
mortality can be seen if delivery of such pregnancies occurs even one week later (e.g. from 73 
26 to 27 weeks) and if there are modest increases in birth weight (eg 100g). In an EU and US 74 
multi-centre observational study of babies born after severe early onset FGR, median survival 75 
gained per day in utero between 24 and 27 weeks of gestation was 2% (range 1.1 – 2.6) (11). 76 
It is in these severe early-onset cases of IUGR that novel therapeutics are initially being 77 
considered, where the benefit of gaining in gestation length or improved fetal weight might 78 
outweigh the potential risks of a novel therapy. If it is found to be safe and efficacious there 79 
is potential to use new therapies in more moderate FGR, which affects a larger number of 80 
pregnancies. 81 
 82 
Gene therapy 83 
Gene therapy allows for the transfer of genetic material into a target cell with the aim of 84 
achieving therapeutic benefit. Since the first gene therapy trials in the 1990s, the hope has 85 
been that gene therapy could improve the management and outcomes of genetic diseases, 86 
particularly single-gene disorders.  There are currently over 1800 completed or on-going gene 87 
therapy clinical trials, of which over two-thirds are for cancer. In 2012 GlyberaTM, a 88 
treatment for familial lipoprotein lipase deficiency became the first gene therapy product to 89 
be approved for licensing in Europe (12). Gene therapies are increasingly reaching clinical 90 
use for treatment of a wide range of inherited single gene disorders such as haemophilia, 91 
thalassaemia, immunodeficiencies and metabolic storage disorders. Concerns about germline 92 
gene transfer and off-target effects in the fetus however, are holding back translation into the 93 
clinic of fetal-directed gene therapy (13) and currently, it is not considered ethical. Serious 94 
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maternal obstetric diseases such as pre-eclampsia and IUGR also affect the fetus and neonate 95 
long term. Targeting gene therapy to the mother and not the fetus, with a view to improve 96 
fetal outcome is considered acceptable from an ethical, legal and regulatory perspective (14). 97 
Appreciating the molecular basis of untreatable obstetric diseases has lead to an 98 
understanding of the potential role that gene therapy could play (8) through manipulation of 99 
angiogenic proteins such as VEGF. Results of pre-clinical studies are compelling and clinical 100 
trials are being planned.  101 
The choice of vector is critical in gene therapy. Manufacture of the vector would ideally be 102 
simple and cost-effective. Clinical grade manufactured vectors need to be tested rigorously 103 
for replication competent viruses. Vectors should be capable of being targeted to the specific 104 
tissue or organ and generate a transgenic protein for the required length of time to have a 105 
therapeutic effect without causing side effects (13). For obstetric conditions such as IUGR 106 
and placental insufficiency, the therapeutic time frame would be short, limited by the length 107 
of gestation. When targeting specific organs such as the uteroplacental circulation, the 108 
method of delivery can have considerable impact on the level and site of genetic expression. 109 
For the above reasons short acting vectors such as adenovirus (Ad.) and non-viral vectors 110 
have been most often investigated in maternal gene therapy for obstetric conditions 111 
(15)(16)(17)(18,19)(20–25).  112 
Adenoviral vectors efficiently transfect a wide range of cells, producing short-term protein 113 
expression, and are the most commonly used vectors in clinical trials of gene therapy (12). 114 
One of their well-recognised side-effects, however, is the potential to trigger both a B cell 115 
and T cell mediated immune reaction. This is being addressed by recent development of less 116 
immunogenic adenoviral vectors or to select serotypes to which fewer patients have pre-117 
existing immunity (26). Adenoviral vectors enter cells through the binding of fibre proteins 118 
on their outer capsid to the coxsackie and adenovirus receptor (CAR). While this receptor is 119 
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found on a wide range of cell types, it has very limited expression on the syncytiotrophoblast. 120 
This could be an advantage for a gene therapy aiming to target the maternal uteroplacental 121 
circulation without transducing the placenta. An alternative is to inject vectors directly into 122 
the placenta (27) but this runs the risk of large amounts reaching the fetal circulation because 123 
of breaches to the fetal villous architecture, effectively becoming a fetal gene transfer 124 
technique. 125 
 126 
Vascular Endothelial Growth Factor 127 
Members of the Vascular Endothelial Growth Factor (VEGF) family and their receptors are 128 
key regulators in the growth and development of blood vessels within the placental villi (28). 129 
So far seven VEGF proteins have been identified, of which VEGF A, B, C, and D, and 130 
Placental Growth Factor (PlGF) are found in humans. Vasculogenesis, the formation of new 131 
blood vessels, and angiogenesis or blood vessel growth both result from the binding of 132 
VEGF-A, or the processed forms of VEGF-C and VEGF-D, to VEGF receptor 2 (VEGFR-2). 133 
Activation of VEGFR-2 causes endothelial cell proliferation and migration, increased 134 
endothelial cell survival, increased vascular permeability, and activation of endothelial nitric 135 
oxide synthase (eNOS). This last effect also vasodilates through increased nitric oxide (NO) 136 
synthesis. In contrast, the soluble form of VEGFR-1, soluble fms-like tyrosine kinase 1 (sFlt-137 
1), binds VEGF-A and PlGF, inhibiting their actions. 138 
In IUGR and placental insufficiency the normal balance of these factors shift towards an anti-139 
angiogenic state, with increased sFlt-1 concentration and a reduction in the maternal 140 
bioavailable VEGF-A and PlGF (29)(4). Correcting this imbalance is therefore a potential 141 
strategy for treating FGR.  Infusion of recombinant VEGF-A121 attenuated some features of 142 
pre-eclampsia and IUGR in pregnant mice and rats that were induced either by adenovirus 143 
vector overexpression of sFlt1 (30)(31) or by infusions of the antibody IgG from women with 144 
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pre-eclampsia (32). However, given the angiogenic and vasodilatory actions of VEGF, it may 145 
be preferable to target increased VEGF availability to the maternal uteroplacental circulation 146 
using locally delivered gene therapy, rather than increase systemic maternal VEGF levels. 147 
Therapeutic angiogenesis is the term given to the induction of new blood vessel formation by 148 
delivering angiogenic genes to ischemic tissues (30). Ad.VEGF gene therapy is being 149 
translated into the clinic for ischemic cardiovascular disorders, including acute myocardial 150 
infarction, chronic cardiac ischemia, peripheral artery disease and stroke. Therapeutic 151 
angiogenesis can also be applied in the maternal uteroplacental circulation as a way to 152 
improve fetal growth in utero, as described below. 153 
 154 
Preclinical Studies on Maternal Uterine Artery VEGF Gene 155 
Therapy 156 
Maternal application of VEGF gene therapy has been tested in a variety of pre-clinical 157 
studies using adenovirus vectors.  The choice of VEGF protein is important because of their 158 
different effects mediated via VEGF receptors and neuropilins. The major VEGF-A isoform, 159 
VEGF-A165, is the predominant and most potent form in humans and it binds to VEGF 160 
Receptors 1 and 2. VEGF-D acts via VEGF Receptors 2 and 3. Both are angiogenic, but 161 
VEGF-D appears to have a more favourable structural and functional profile than that of 162 
VEGF-A165, eliciting a more restricted range of biological responses and may therefore have 163 
fewer side effects, making it the agent of choice for therapeutic angiogenesis. 164 
Equally it is now known that the type of VEGF isoform can critically regulate VEGF 165 
function. This can be through the endothelial response, for example, the 165 and 121 166 
isoforms of VEGF-A can elicit differential signal transduction and endothelial responses 167 
through programming VEGFR2 endocytosis, ubiquitylation and proteolysis (31). 168 
Alternatively different binding of VEGF-A isoforms to the co-receptors heparin sulphate and 169 
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neuropilin-1 differentiates the effects of VEGF-A165 that binds both and mediates angiogenic 170 
sprouting and endothelial cell organization, from VEGF-A121 that binds neither and therefore 171 
lacks these functions (32).  172 
The impact of Ad.VEGF on uterine blood flow (UBF) was first examined at mid-gestation in 173 
uncompromised normal sheep pregnancies using the VEGF-A165 isoform. Results are 174 
summarised in Table 1. UBF was quantified at baseline and at 4-7 days following direct 175 
uterine artery (UtA) injection of Ad.VEGF-A165 at laparotomy. The artery was digitally 176 
occluded during vector injection and afterwards for up to 5 minutes total time to maximise 177 
transduction of the downstream endothelium (20). By 4-7 days, volume blood flow in the 178 
UtA was increased three-fold when compared to a contralateral UtA injection of a non-179 
vasoactive control adenoviral vector encoding bacterial ß-galactosidase (Ad.LacZ). 180 
Ad.VEGF-A165 transduced vessels harvested at this short-term time point demonstrated an 181 
enhanced contractile response to phenylephrine and increased relaxation response to 182 
bradykinin when examined in an organ bath, as well as upregulation of endothelial nitric 183 
oxide synthase (eNOS) and VEGFR-2 (22).  Using adenovirus containing the unprocessed 184 
VEGF-D isoform found no effect.  Further experiments using the pre-processed short-form of 185 
Ad.VEGF-D (Ad.VEGF-D∆N∆C) demonstrated similar effects on vasoreactivity, up-regulation 186 
of phosphorylated eNOS and enhanced UtA endothelial cell proliferation (22), but without 187 
the uterine artery inflammatory infiltrate that was observed after Ad.VEGF-A165 transduction 188 
(20).  189 
The effects of Ad.VEGF- A165 on UBF long term were examined using indwelling ultrasonic 190 
flow probes in normal sheep pregnancies. Using an identical injection protocol, at 28 days 191 
post-injection, vessels treated with Ad.VEGF- A165 exhibited a 36.5% increase in UBF 192 
compared to just 20.1% in vessels treated with Ad.LacZ (21), which represents a virtual 193 
doubling of the normal gestational increase in UBF. A similar tendency was observed long-194 
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term after injection of Ad.VEGF-D∆N∆C (22). In both long term studies, reduced 195 
phenylephrine-induced vasoconstriction continued to be observed but changes in 196 
vasorelaxation and VEGFR-2 expression were no longer evident. Nevertheless at 197 
approximately 30 days following treatment there was still evidence of neovascularisation 198 
within the perivascular adventitia despite undetectable levels of transgenic VEGF protein. 199 
This suggests that the vasoactive effects of Ad.VEGF persist beyond the period of transgenic 200 
protein expression, probably via angiogenesis mechanisms, an effect that has been seen in 201 
many other vascular beds.  202 
The effect of Ad.VEGF-mediated changes in UBF on fetal growth has been examined in two 203 
preclinical animal models of IUGR (Table 2). High nutritional intake in pregnant adolescent 204 
dams at a time when they are still growing promotes maternal tissue growth at the expense of 205 
the pregnancy leading to marked IUGR in approximately half of pregnancies (33). This 206 
IUGR sheep paradigm replicates many of the key features of uteroplacental FGR in the 207 
human including early reductions in UBF (>40%), placental weight, vascularity, secretory 208 
function and mRNA expression of VEGF and VEGFR-1, followed by asymmetrical IUGR 209 
characterised by brain sparing (preserved head growth with reduced abdominal growth) and 210 
abnormal umbilical artery Doppler velocimetry (34).  In two separate IUGR sheep cohorts, 211 
following bilateral UtA injections of Ad.VEGF-A165 in mid-gestation, ultrasound abdominal 212 
circumference measurements were increased by approximately 20% when examined at three 213 
and four weeks following treatment compared to animals with equivalent baseline 214 
measurements receiving control treatments (Ad.LacZ or saline only, Table 2) (24,25).  There 215 
was evidence of an attenuated brain sparing effect (catch up of abdominal to head growth). 216 
Significantly fewer Ad.VEGF-A165 treated fetuses demonstrated marked FGR at term (24), 217 
lamb birthweight tended to be higher (25), and in both studies there was evidence of 218 
increased placental efficiency (g fetus/lamb per g placenta). Postnatally Ad.VEGF-A165-219 
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treated lambs continued to grow faster in absolute terms throughout the first 12 weeks of life 220 
in the absence of any change in fractional growth velocity or markers of adiposity (Table 2). 221 
DNA methylation studies found no evidence of altered epigenetic status in ten different genes 222 
related to postnatal growth and metabolism.  223 
In a second animal model of FGR induced by periconceptual nutrient deprivation of Dunkin 224 
Hartley guinea pigs, complementary experiments have demonstrated similar efficacy, safety 225 
and mechanism of action of Ad.VEGF gene therapy to improve fetal growth and neonatal 226 
outcome. Placentation in this species more closely mimics the human, being haemochorial in 227 
nature, and shares a similar process of trophoblast cell invasion and proliferation (35). In this 228 
FGR model there is an approximate 40% reduction in fetal weight associated with 229 
uteroplacental insufficiency and brain sparing (36). As direct injection of the UtA in the 230 
guinea pig is associated with considerable morbidity and mortality, a less invasive technique 231 
of administration has been developed using a thermosensitive Pluronic gel, which is applied 232 
externally to the uterine and radial arteries at laparotomy to achieve transduction with 233 
Ad.VEGF-A165 or Ad.LacZ at 30-34 days gestation (term = 65) (37). Using this technique, 234 
Ad.VEGF-A165 treatment improved fetal growth at term and a lower brain: liver weight ratio, 235 
implying that brain sparing had been mitigated (Table 2) (38). More recently in a second 236 
delivered cohort, there are no adverse effects on perinatal morbidity or mortality, improved 237 
postnatal growth and amelioration of the increase in adult blood pressure associated with 238 
IUGR in this animal model (submitted, Table 2). 239 
The improvements in fetal birth weight and uterine artery blood flow in IUGR-animal models 240 
treated with Ad.VEGF establish VEGF as a transgenic factor with therapeutic benefit in 241 
IUGR-affected pregnancies, making it a strong candidate for translation into human clinical 242 
trials. Extrapolating from animal studies to humans is challenging particularly for pregnancy 243 
conditions where animal models of disease may not completely recapitulate the disease (35) 244 
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and where they may be fundamental differences in VEGF biology and VEGF measurement 245 
techniques (39). 246 
 247 
 248 
Risks of maternal uterine artery VEGF gene therapy 249 
An important consideration for any prenatal therapy is safety, some data of which is 250 
presented in Table 1 and 2. This therapy aims to reduce or eliminate the adverse effects of 251 
poor growth in the fetus without exposing the fetus to significant amounts of the vector.  252 
Transfer of a gene therapy across the placenta to the fetus in significant quantities would be 253 
undesirable, as it would risk germline transmission and may have adverse effects on fetal 254 
development. Current evidence suggests that the extent of placental transfer depends on the 255 
vector, the animal, the route of administration, and the gestation age at which it is 256 
administered. In the pre-clinical studies of maternal Ad.VEGF gene transfer, local delivery to 257 
the uterine arteries has been achieved either by direct injection combined with proximal 258 
occlusion of the vessel or by external application of a thermolabile Pluronic gel to the vessel 259 
wall (37). These delivery methods do not lead to evidence of detectable vector in the sheep or 260 
guinea pig fetus. Exposure of human placental villous explants to high dose Ad. vector 261 
showed that, where the syncytiotrophoblast was deficient there was occasional transduction 262 
of the underlying cytotrophoblast, but no evidence of the vector crossing the basement 263 
membrane (40). In translation to clinical practice this could be replicated using a balloon 264 
catheter, introduced into each uterine artery in turn using x-ray guided interventional 265 
radiology. This technique has been used for over 30 years to treat fibroids and manage 266 
postpartum haemorrhage, and is now being used increasingly during pregnancy, with 267 
catheters and deflated balloons placed into the uterine arteries before Caesarean section when 268 
heavy bleeding is anticipated (41).  269 
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Vector modification of the fetal germ line could theoretically occur following maternal gene 270 
therapy. This would be dependent first on whether the vector reached the fetus, and then was 271 
able to access the germline. The gestational age of the fetus and route of injection are 272 
probably the determining factors for germline gene transfer risk. Early gestation direct fetal 273 
gene therapy leads to germline transmission when retroviral vectors are injected into the 274 
peritoneal cavity of first trimester fetal sheep (60), and after first trimester but not second 275 
trimester intraperitoneal injection of lentiviral vectors into fetal macaque monkeys (61). 276 
Compared with direct fetal gene therapy therefore, maternal uterine artery gene therapy for 277 
IUGR that is will be conducted after mid gestation should carry a very low risk of fetal 278 
germline transduction. This is an important safety consideration in any clinical trial protocol.   279 
Data derived from pre-clinical studies show no evidence of placental toxicity. T cells and 280 
macrophages were not markedly increased in the placenta of pregnant rabbits treated with an 281 
Ad. vector (42). Ex vivo studies assessing the effect of an Ad.VEGF vector on human 282 
placental villous explants showed no changes in the expression of enzymes associatd with 283 
placental dysfunction such as lactate dehydrogenase and human chorionic gonadotropin (40).  284 
 285 
The EVERREST consortium of academic health science centres, universities and small 286 
medium enterprises was awarded European Commission funding to investigate the efficacy 287 
and safety of Ad.VEGF therapy in pregnant women diagnosed with severe early onset IUGR 288 
through phase I/IIa clinical trials (43). The consortium were awarded orphan drug status from 289 
the European Committee for Orphan Medicinal Products for FGR, the first time that a drug 290 
has been recognised for the treatment of FGR. In stakeholder and patient interviews 291 
conducted by the EVERREST consortium, maternal gene therapy was for the majority of 292 
stakeholders considered to be acceptable if there was clear fetal benefit (44). Most women 293 
felt they would be able to make informed decisions about taking part in such a trial whilst 294 
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pregnant, so long as they were provided with the information required to make an 295 
autonomous decision.  The primary aim of the the phase I clinical trial is to determine safety. 296 
The planned route of administration is via interventional radiology guided uterine artery 297 
injection, with a temporary cessation of blood flow during vector injection of up to 5 minutes. 298 
There are concerns that systemic gene transfer with generalised transgenic VEGF expression 299 
would detrimentally lower maternal blood pressure and reduce uteroplacental perfusion, such 300 
as was seen after systemic administration of sildenafil citrate in FGR sheep pregnancy (45).   301 
Temporary cessation of uterine artery blood flow could potentially worsen fetal hypoxia. It is 302 
now appreciated from radiological studies however, that the the uterus is provided by a rich 303 
blood supply from the ovarian, cervical and vaginal arteries including a system of utero-304 
ovarian communicating arteries (46)(47)(48). Careful monitoring of fetal wellbeing and 305 
prompt release of uterine artery occlusion will be needed in any clinical trial protocol. 306 
Other potential risks include vascular leak, which is less likely when using VEGF-D rather 307 
than VEGF-A isoforms, and the pro-inflammatory state from VEGF-induced macrophage 308 
activation. Reassuringly long term studies on adenovirus gene therapy show an excellent 309 
safety profile up to 10 years after clinical trials of local intracoronary and lower limb 310 
administration (49)(50), and Ad.VEGF-D∆N∆C is being tested in a phase III clinical trial for 311 
refractory angina pectoris “ReGenHeart” ClinicalTrials.gov Identifier:NCT03039751. 312 
The consortium has developed a prospective “natural history” cohort, to carefully define the 313 
characteristics and outcomes of pregnancies affected by severe early onset IUGR (51) which 314 
is also refining the inclusion criteria for a clinical trial. During this study the consortium has 315 
also studied which angiogenic markers may be most useful for defining the inclusion criteria 316 
in the trial.  Monitoring the change in concentration of sFlt1 and its ratio with PlGF may be 317 
useful to predict the onset of pre-eclampsia and IUGR (52), and a similar approach is being 318 
investigated. This will need to ensure that only those women with the most severely affected 319 
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pregnancies take part, while achieving sufficient numbers of babies to allow long term to 320 
evaluate safety and efficacy.  321 
 322 
Conclusion 323 
Local expression of VEGF in the uterine arteries increases uterine blood flow, alters uterine 324 
artery vascular reactivity, increases angiogenesis and improves fetal growth in IUGR 325 
pregnancies without apparent maternal or fetal harm. Translation to the clinic will be 326 
complex as getting informed patient consent and demonstrating safety will be key. Findings 327 
from preclinical studies however suggest that maternal VEGF gene therapy is promising as a 328 
therapy for severe early onset IUGR. 329 
 330 
  331 
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Figure Legends 348 
 349 
Figure 1: 350 
Sites of action in the uteroplacental circulation and blood, of the interventions currently under 351 
investigation as treatments for intrauterine growth restriction and pre-eclampsia. sFlt-1, 352 
soluble fms-like tyrosine kinase 1; VEGF, vascular endothelial growth factor; NOS, nitric 353 
oxide synthase; NO, nitric oxide; sGC, soluble guanylate cyclase; 354 
GTP, guanosine-5′-triphosphate; cGMP, cyclic guanosine monophosphate; 5′ GMP, 355 
guanosine monophosphate; PDE5, phosphodiesterase type 5 inhibitor  356 
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Effect 
Short term (4-7 days after vector injection) Long term (28-30 days after vector injection) 
Ad.VEGF-A165 Ad. VEGF-D∆N∆C Ad.VEGF-A165 Ad. VEGF-D∆N∆C 
Uterine artery blood flow * - * tendency to  
Tissue VEGF expression by  
ELISA and 
Immunohistochemistry 
Injected uterine artery 
Perivascular adventitia 
Injected uterine artery 
Perivascular adventitia Not detectable Not detectable 
Blood VEGF expression Maternal, no fetal Maternal, no fetal Not detectable Not detectable 
Uterine artery adventitial 
angiogenesis * * * * 
Vascular contractility * * * * 
Vascular relaxation * *   
Vector spread Maternal / no fetal - - - 
Histological analysis Oedema and 
macrophage infiltration No abnormality No abnormality No abnormality 
VEGF Receptors VEGFR2 -   
eNOS Western blot     
Maternal BP and HR     
Fetal BP and HR     
 
Table 1: Results of Ad.VEGF delivery to the uterine arteries of normal sheep pregnancies (17,18,19). *p < 0.05.  eNOS: endothelial nitric oxide 
synthase; BP: blood pressure; HR: heart rate 
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Model Over-nourished adolescent ewe (IUGR sheep) Maternal nutrient restricted IUGR guinea pig 
Time of 
assessment 
Term pregnancy 3 months postnatal 3-7 days post vector 
application 
30 days post 
vector application 
4 months postnatal 
Vector dose 1×1012/ewe 1×1012/ewe 1x1010vps/animal 1x1010vps/animal 1x1010vps/animal 
Uterine artery 
blood flow 
n=18: No change 
detectable  
Not done Not applicable Not applicable Not applicable 
Fetal and 
neonatal 
growth 
velocity 
n=18:  Fetal 
abdominal 
circumference 
≈20% greater. 
Significantly fewer 
severe IUGR lambs 
n=17: Fetal abdominal 
circumference ≈20% 
greater.  Lamb birth 
weight tended to be ≈20% 
greater near term. Higher 
absolute neonatal growth 
rate.  
Not applicable n=45: Increased 
birthweight, 
increased brain, 
lung and liver 
weights 
n=15: Increased 
birthweight, increased 
neonatal growth. 
Amelioration of adult 
hypertension 
Maternal, 
fetal and 
neonatal 
health 
No AEs (n=18) No AEs (n=17) No AEs (n=10) No AEs (n=12) No AEs (n=15) 
Presence or 
expression of 
vector 
RT-PCR: increased  
VEGF receptor 
(FLT1/KDR) 
mRNA expression 
in the maternal but 
not fetal placental 
compartments  
not done RT-PCR: fetal 
tissues (-), 
transduced Uterine 
and Radial Artery 
(+), all other 
maternal tissues (-).   
ELISA: transduced 
Uterine and Radial 
Artery (+) 
RT-PCR: fetal (-) 
ELISA: (-) 
Not done 
Table 2: Efficacy and safety of Ad.VEGF-A165 in preclinical FGR animal studies (20-22).   
AE: Adverse Event; RT-PCR=Real time polymerase chain reaction; FLT-1=Vegfr 1; KDR=Vegfr 2 
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